New treatment options for lung cancer. Lung cancer is a leading cause of death world wide 90% of lung cancer is caused by smoking 20% of patients are suitable for surgery 5% of all cases have 5 year survival. Most of the patients are in advanced stages and have very poor prognosis
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
New treatment options for lung cancer
The second class of EGFR agents is represented by Cetuximab.
It is a MONOCLONAL ANTIBODY that binds to EGFR and inhibits intracellular phosphorylation of EGFR and its signaling pathways.
Cetuximab is less potent than Erlotinib/Gefinib, it has its definite advantages. Cetuximab demonstrated to be effective on Gefitinib resistant mutant EGFR
Angiogenesis is one of the hallmarks of tumor formation. Majority of NSCLC tumors express vascular endothelial growth factor (VEGF). Studies proved that the higher expression of VEGF correlate with poor prognosis for lung cancer patients (Herbst, 2006).
Bevasizumab is a recombinant humanized monoclonal antibody against VEGF